Mostrar el registro sencillo del ítem
Development of a prediction model for short-term remission of patients with Crohn’s disease treated with anti-TNF drugs
dc.contributor.author | Medina-Medina, Rosario | |
dc.contributor.author | Iglesias-Flores, Eva | |
dc.contributor.author | Benítez, José M. | |
dc.contributor.author | Marín-Pedrosa, Sandra | |
dc.contributor.author | Salgueiro-Rodríguez, Isabel | |
dc.contributor.author | Linares Luna, Clara Isabel | |
dc.contributor.author | González Rubio, Sandra | |
dc.contributor.author | Soto-Escribano, Pilar | |
dc.contributor.author | Gros, Beatriz | |
dc.contributor.author | Rodríguez-Perálvarez, Manuel | |
dc.contributor.author | Cabriada, José L. | |
dc.contributor.author | Chaparro, María | |
dc.contributor.author | Gisbert, Javier P. | |
dc.contributor.author | Chicano-Gálvez, Eduardo | |
dc.contributor.author | Ortega, Ignacio | |
dc.contributor.author | Ferrín, Gustavo | |
dc.contributor.author | García-Sánchez, Valle | |
dc.contributor.author | Aguilar-Melero, P. | |
dc.date.accessioned | 2023-05-30T12:50:25Z | |
dc.date.available | 2023-05-30T12:50:25Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | http://hdl.handle.net/10396/25437 | |
dc.description.abstract | Therapy with anti-tumor necrosis factor (TNF) has dramatically changed the natural history of Crohn’s disease (CD). However, these drugs are not without adverse events, and up to 40% of patients could lose efficacy in the long term. We aimed to identify reliable markers of response to anti-TNF drugs in patients with CD. A consecutive cohort of 113 anti-TNF naive patients with CD was stratified according to clinical response as short-term remission (STR) or non-STR (NSTR) at 12 weeks of treatment. We compared the protein expression profiles of plasma samples in a subset of patients from both groups prior to anti-TNF therapy by SWATH proteomics. We identified 18 differentially expressed proteins (p ≤ 0.01, fold change ≥ 2.4) involved in the organization of the cytoskeleton and cell junction, hemostasis/platelet function, carbohydrate metabolism, and immune response as candidate biomarkers of STR. Among them, vinculin was one of the most deregulated proteins (p < 0.001), whose differential expression was confirmed by ELISA (p = 0.054). In the multivariate analysis, plasma vinculin levels along with basal CD Activity Index, corticosteroids induction, and bowel resection were factors predicting NSTR. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/ | es_ES |
dc.source | Int. J. Mol. Sci., 24(10), 8695 (2023) | es_ES |
dc.subject | Inflammatory bowel disease | es_ES |
dc.subject | Crohn’s disease | es_ES |
dc.subject | SWATH proteomics | es_ES |
dc.subject | Predictive biomarkers | es_ES |
dc.subject | Anti-TNF-a therapy | es_ES |
dc.subject | Vinculin | es_ES |
dc.title | Development of a prediction model for short-term remission of patients with Crohn’s disease treated with anti-TNF drugs | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/ijms24108695 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |